// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Involvement of Orai1 Ca2 channel in the pathogenesis of pulmonary arterial hypertension. Orai1 as a new potential therapeutic target ?

Bastien Masson - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Evidence of target engagement and pathway modulation: biomarker analysis of the phase 1b inhaled seralutinib study

Robin Osterhout - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Seralutinib

Association between Leflunomide and Pulmonary Hypertension

Thomas Lacoste Palasset - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

leflunomide

Convergence of clinical and computational phenotypes for rare variant association study (RVAS) in pulmonary arterial hypertension

Emilia Swietlik - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Current strategies for managing CTEPH

Marion Delcroix - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic thromboembolic pulmonary hypertension

Riociguat

Survival effects of pulmonary vasodilators in group 3 pulmonary hypertension

Timothy Dawes - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary arterial hypertension

N/A

PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH)

David Badesch - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

Sotatercept

Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD): an international research prioritisation

Heba Bintalib - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

Estimating long-term survival in progressive fibrosing interstitial lung disease (PF-ILD) other than IPF using matched IPF data

Toby Maher - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

Nintedanib

Early Supported Discharge with Home Oxygen in COVID-19 Patients

Marcus Anthony Pittman - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Covid-19 related concerns and outcomes from shielding in clinically extremely vulnerable adults and children with neuromuscular disease

Lydia Spurr - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Development of Culturally Appropriate Pulmonary Rehabilitation (PR) for Sri Lanka: A qualitative study

Chamilya Perera - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Effectiveness of triage pathways for prioritising patient care by a multi-disciplinary community respiratory team during the COVID-19 pandemic

Emily Turner - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Process evaluation of the British Lung Foundation Active Steps service

Arwel Jones - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Emerging Pulmonary Rehabilitation (PR) in the digital world

Samantha Pilsworth - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Economic evaluation of the British Lung Foundation Active Steps service

Arwel Jones - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

What should Pulmonary Rehabilitation (PR) look like for adults living with post-TB lung disease (PTBLD) in Kyrgyzstan? A qualitative study

Gulzada Mirzalieva - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Acute exacerbation of COPD- What symptoms bothers patients the most: A survey study

Bedor Alkhathlan - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Maintenance strategy preferences following pulmonary rehabilitation (PR) for patients with chronic respiratory disease (CRD): A Survey

KHALED ALQAHTANI - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The value of a post-polio syndrome self-management programme

Alexandra Curtis - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Copyright © 2026. QuantiNova All rights reserved